Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kosuke Yamazaki

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 18, 2007
[Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]Norikazu Masuda, Masakazu Toi, Yuichi Takatsuka, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2020
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, et al.
International Journal of Clinical Oncology|March 17, 2015
Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
International Journal of Clinical Oncology|February 11, 2015
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 18, 2007
[Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]Norikazu Masuda, Masakazu Toi, Yuichi Takatsuka, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2020
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, et al.
International Journal of Clinical Oncology|March 17, 2015
Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
International Journal of Clinical Oncology|February 11, 2015
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Pageof 3